| GENOMAS, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110312508 | PHYSIOGENOMIC METHOD FOR PREDICTING DIABETES AND METABOLIC SYNDROMES INDUCED BY PSYCHOTROPIC DRUGS - The invention is generally directed to a physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs. In one embodiment, the invention relates to the use of genetic variants of marker genes to predict the likelihood that an individual will experience undesirable metabolic side effects as a result of the use of a drug including, but not limited to, psychotropic drugs. The invention also relates to methods predicting the likelihood of diabetes and metabolic syndromes induced by the use of drugs with undesirable metabolic side effects. | 12-22-2011 |
| 20110098186 | PHYSIOGENOMIC METHOD FOR PREDICTING DRUG METABOLISM RESERVE FOR ANTIDEPRESSANTS AND STIMULANTS - Disclosed herein are compositions and methods relevant to a novel Drug Metabolism Reserve Physiotype to determine the metabolic capacity of a human individual. The Drug Metabolism Reserve Physiotype allows the determination of the innate metabolic capacity of the patient relevant to antidepressant and stimulant treatment and can be predicted and diagnosed simply from a blood sample. In the disclosed method, an individual is genotyped for a plurality of polymorphisms in a gene encoding CYP2C9, a gene encoding CYP2C19 and a gene encoding CYP2D6, and the genotypes are used to produce four novel indices, which relate to the metabolic capacity of the human individual. | 04-28-2011 |
| 20090263814 | Physiogenomic Method for Predicting Metabolic and Cardiovascular Side Effects of Thiazolidinediones - Disclosed herein are genetic markers related to the efficacy and/or safety of thiazolidinedione therapy identified by a physiogenomic methodology that correlates the genetic markers with a physiological response. The genetic markers described herein were not previously associated with the efficacy and/or safety of thiazolidinedione therapy. The markers related to safety are those associated with the important side effects of BMI increase and development of edema. In one embodiment, markers related to efficacy of thiazolidinedione therapy are associated with glycosylated hemoglobin. Method of assessing an individual for markers associated with the safety and/or efficacy of thiazolidinedione therapy are described. | 10-22-2009 |
| 20090233299 | Physiogenomic Method for Predicting Statin Injury to Muscle and Muscle Side Effects - The present invention relates to the use of genetic variants of associated marker genes to predict an individual's susceptibility to muscular injury and muscular side effects in response to statin therapy. The present invention further relates to analytical assays and computational methods using the novel marker gene set. The present invention has utility for personalized medical treatment, drug safety, statin compliance, and prophylaxis of muscle side effect. | 09-17-2009 |
